LOLLINI, PIER LUIGI
 Distribuzione geografica
Continente #
NA - Nord America 11.222
AS - Asia 10.139
EU - Europa 8.894
AF - Africa 608
SA - Sud America 605
OC - Oceania 16
Continente sconosciuto - Info sul continente non disponibili 7
Totale 31.491
Nazione #
US - Stati Uniti d'America 11.044
VN - Vietnam 3.031
IT - Italia 2.730
CN - Cina 2.676
SG - Singapore 2.455
GB - Regno Unito 1.749
DE - Germania 996
HK - Hong Kong 636
SE - Svezia 615
FR - Francia 519
IN - India 436
BR - Brasile 406
UA - Ucraina 397
RU - Federazione Russa 387
CH - Svizzera 294
NL - Olanda 266
IE - Irlanda 256
KR - Corea 209
CI - Costa d'Avorio 202
JP - Giappone 193
ZA - Sudafrica 176
FI - Finlandia 129
EE - Estonia 122
CA - Canada 106
TG - Togo 93
BG - Bulgaria 66
ID - Indonesia 62
AR - Argentina 60
BE - Belgio 59
CO - Colombia 59
PH - Filippine 52
TH - Thailandia 52
MX - Messico 47
SC - Seychelles 46
TR - Turchia 44
JO - Giordania 43
PL - Polonia 43
AT - Austria 38
IQ - Iraq 38
RO - Romania 35
BD - Bangladesh 34
GR - Grecia 33
ES - Italia 32
PK - Pakistan 31
NG - Nigeria 27
LU - Lussemburgo 26
TW - Taiwan 26
CL - Cile 23
EC - Ecuador 22
LT - Lituania 22
EG - Egitto 21
SA - Arabia Saudita 19
HR - Croazia 16
AU - Australia 14
IR - Iran 14
PE - Perù 13
UZ - Uzbekistan 12
MY - Malesia 11
AL - Albania 10
DZ - Algeria 10
VE - Venezuela 10
AZ - Azerbaigian 9
CR - Costa Rica 9
DK - Danimarca 9
AE - Emirati Arabi Uniti 8
LB - Libano 8
MA - Marocco 7
KE - Kenya 6
PT - Portogallo 6
RS - Serbia 6
SK - Slovacchia (Repubblica Slovacca) 6
TN - Tunisia 6
CZ - Repubblica Ceca 5
KZ - Kazakistan 5
MD - Moldavia 5
UY - Uruguay 5
DO - Repubblica Dominicana 4
EU - Europa 4
GE - Georgia 4
HU - Ungheria 4
KH - Cambogia 4
LV - Lettonia 4
PY - Paraguay 4
TJ - Tagikistan 4
BO - Bolivia 3
HN - Honduras 3
IL - Israele 3
MN - Mongolia 3
PS - Palestinian Territory 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AM - Armenia 2
AO - Angola 2
BY - Bielorussia 2
GH - Ghana 2
JM - Giamaica 2
KG - Kirghizistan 2
LI - Liechtenstein 2
NI - Nicaragua 2
OM - Oman 2
SI - Slovenia 2
Totale 31.462
Città #
Singapore 1.682
Southend 1.447
Fairfield 1.209
Ashburn 1.120
Chandler 880
Ho Chi Minh City 647
Hong Kong 605
Houston 581
Hanoi 576
Bologna 563
Woodbridge 561
Wilmington 546
Seattle 497
Hefei 489
Ann Arbor 451
San Jose 429
Cambridge 387
Dong Ket 365
Princeton 360
Santa Clara 342
Beijing 295
Jacksonville 257
Bern 253
Dublin 253
Boardman 243
Abidjan 202
Shanghai 201
Lauterbourg 190
Seoul 179
Milan 178
Tokyo 170
Council Bluffs 157
Nanjing 155
Dallas 153
Westminster 147
Los Angeles 145
Padova 141
Frankfurt am Main 127
Berlin 111
Lomé 93
Rome 93
Buffalo 89
Helsinki 89
Jinan 87
Haiphong 86
Turin 80
Bremen 79
New York 77
Shenyang 76
Guangzhou 75
Da Nang 73
Saint Petersburg 73
San Diego 71
Sofia 65
Changsha 61
Nanchang 55
Mülheim 54
Brussels 53
Redwood City 52
São Paulo 52
Redondo Beach 51
London 49
Hebei 47
Tianjin 47
Amsterdam 46
Jakarta 46
Bengaluru 45
Amman 42
Falkenstein 40
Jiaxing 40
Redmond 40
Phoenix 39
Johannesburg 38
Medford 38
Biên Hòa 37
Falls Church 36
Casalecchio di Reno 35
Hải Dương 35
Naples 35
Des Moines 34
Zhengzhou 34
Toronto 31
Warsaw 31
Verona 30
Can Tho 29
Lappeenranta 29
Mahé 29
Paris 29
Ottawa 28
Chicago 27
Hangzhou 27
Florence 26
Haikou 26
Parma 26
Yubileyny 26
Luxembourg 25
Vienna 25
The Dalles 24
Abeokuta 23
Dearborn 23
Totale 20.195
Nome #
Vaccini antitumorali 974
IFN-γ and CD38 in Hyperprogressive Cancer Development 427
Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER-2. 380
ROCK2 deprivation leads to the inhibition of tumor growth and metastatic potential in osteosarcoma cells through the modulation of YAP activity 373
Terapia genica 347
Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft 338
Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations 317
Integrated molecular characterization of patient-derived models reveals therapeutic strategies for treating CIC-DUX4 sarcoma 279
Abstract 5909: IDH mutations in G2-3 conventional chondrosarcoma of bone: a mono institutional experience 273
Different mtDNA mutations modify tumor progression in dependence of the degree of respiratory complex I impairment 265
A multi-DNA preventive vaccine for p53/Neu driven cancer syndrome 265
Respiratory complex I is essential to induce a Warburg profile in mitochondria-defective tumor cells 257
Development of a K-edge micro CT for the study of tumor angiogenesis in small animals 246
Preclinical therapy of disseminated HER-2+ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus. 245
Cancer Vaccines Co-Targeting HER2/Neu and IGF1R 244
A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors 241
CD99 contributes to the EWS::FLI1 transcriptome by specifically affecting FOXM1-targets involved in the G2/M cell cycle phase, thus influencing the Ewing sarcoma genetic landscape 237
Rethinking herpes simplex virus: the way to oncolytic agents. 232
Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases 232
Virus-like particle display of HER2 induces potent anti-cancer responses 229
Multiorgan Metastasis of Human HER-2+ Breast Cancer in Rag2−/−;Il2rg−/− Mice and Treatment with PI3K Inhibitor 227
A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy 226
PD-L1 and IFN-γ modulate Non-Small Cell Lung Cancer (NSCLC) cell plasticity associated to immune checkpoint inhibitor (ICI)-mediated hyperprogressive disease (HPD) 219
CD99 suppresses osteosarcoma cell migration through inhibition of ROCK2 activity. 218
Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells. 216
Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1 212
Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression 212
CD99 Acts as an Oncosuppressor in Osteosarcoma. 211
ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1- rearranged NSCLC 210
Apc10.1: an ApcMin/+ intestinal cell line with retention of heterozygosity. 210
Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy 209
IDH mutations in G2-3 conventional central bone chondrosarcoma: a mono institutional experience 204
Functional evaluation of circulating anti-cancer antibodies with a 3D tumor cell growth inhibition assay 204
Cancer immunoprevention: from mice to early clinical trials 203
Insulin-like growth factor 2 mRNA-binding protein 3 is a novel post-transcriptional regulator of Ewing sarcoma malignancy 203
Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model 201
Advances in preclinical therapeutics development using small animal imaging and molecular analyses: the gastrointestinal stromal tumors model. 201
Circulating miR34a levels as a potential biomarker in the follow-up of Ewing sarcoma 201
Endothelin-3 production by human rhabdomyosarcoma: A possible new marker with a paracrine role. 200
Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice. 199
Cancer vaccines: Target antigens, vaccine platforms and preclinical models 197
In silico modeling and in vivo efficacy of cancer preventive vaccinations 197
HER-2/neu tolerant and non-tolerant mice for fine assessment of antimetastatic potency of dendritic cell-tumor cell hybrid vaccines 196
Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET. 195
A better immune reaction to Erbb-2 tumors is elicited in mice by DNA vaccines encoding rat/human chimeric proteins 194
ImmunoGrid: Towards agent-based simulations of the human immune system at a natural scale 193
An aza-macrocycle containing maltolic side-arms (maltonis) as potential drug against human pediatric sarcomas. 191
Evaluation of metastatic burden and recovery of human metastatic cells from a mouse model 191
Lamin A and the LINC complex act as potential tumor suppressors in Ewing Sarcoma 191
CD99 drives terminal differentiation of osteosarcoma cells by acting as a spatial regulator of ERK 1/2. 190
A Mutation Threshold Distinguishes the Antitumorigenic Effects of the Mitochondrial Gene MTND1, an Oncojanus Function 190
The mechanisms of PD-L1 regulation in non-small-cell lung cancer (NSCLC): Which are the involved players? 190
Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations 189
Immune targeting of autocrine IGF2 hampers rhabdomyosarcoma growth and metastasis 187
Targeting CD99 compromises the oncogenic effects of the chimera EWS-FLI1 by inducing re-expression of zyxin and inhibition of Gli1 activity 187
Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. 185
Antimetastatic activity of a preventive cancer vaccine. 185
Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis 184
Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice. 184
Biological indicators of prognosis in Ewing’s sarcoma: an emerging role for lectin galactoside-binding soluble 3 binding protein (LGALS3BP). 184
Human responses against HER-2-positive cancer cells in human immune system-engrafted mice. 184
High metastatic efficiency of human sarcoma cells in Rag2/gamma c double knockout mice provides a powerful test system for antimetastatic targeted therapy 184
Synovial Sarcoma Preclinical Modeling: Integrating Transgenic Mouse Models and Patient-Derived Models for Translational Research 183
Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma. 182
Engagement of CD99 activates distinct programs in Ewing sarcoma and macrophages 181
Herpesviruses as oncolytic agents 179
Prevention and Therapy of Metastatic HER-2+ Mammary Carcinoma with a Human Candidate HER-2 Virus-like Particle Vaccine 178
Virus-like Particle (VLP) Vaccines for Cancer Immunotherapy 178
Opposing control of rhabdomyosarcoma growth and differentiation by myogenin and interleukin 4. 177
Lipid rafts, caveolae, and epidermal growth factor receptor family: friends or foes? 176
CRISPR/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mortality 176
Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer 176
CD99 isoforms dictate opposite functions in tumour malignancy and metastases by activating or repressing c-Src kinase activity 176
Genetic algorithm against cancer. 175
Modeling the competition between lung metastases and the immune system using agents. 175
HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response 175
OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis 174
Oncolytic herpes virus retargeted to HER-2. 173
Expression of a functional CCR7 chemokine receptor inhibits the post-intravasation steps of metastasis in malignant murine mammary cancer cells 171
Immunoprevention and immunotherapy of mammary carcinoma 171
ABCA6 affects the malignancy of Ewing sarcoma cells via cholesterol-guided inhibition of the IGF1R/AKT/MDM2 axis 170
Genetic prevention of lymphoma in p53 knockout mice allows the early development of p53-related sarcomas 169
Correction to: ABCA6 affects the malignancy of Ewing sarcoma cells via cholesterol-guided inhibition of the IGF1R/AKT/MDM2 axis 168
Metformin as an adjuvant drug against pediatric sarcomas: hypoxia limits therapeutic effects of the drug. 167
Rhabdomyosarcomas are potential target of MAGE-specific immunotherapies. 166
Vaccines for tumour prevention 164
The Promise of Preventive Cancer Vaccines 164
Immunological prevention of a multigene cancer syndrome 164
Activated d16HER2 Homodimers and SRC Kinase Mediate Optimal Efficacy for Trastuzumab. 163
Translational immunomics of cancer prevention. 162
Evaluation of Modified PEG-Anilinoquinazoline Derivatives as Potential Agents for EGFR Imaging in Cancer by Small Animal PET. 162
A novel paradigm for cell and molecule interaction ontology: from the CMM model to IMGT-ONTOLOGY 161
TRAF6 regulates proliferation and differentiation of skeletal myoblasts 161
Expression levels of insulin receptor substrate-1 modulate the osteoblastic differentiation of mesenchymal stem cells and osteosarcoma cells. 161
Expression of connective tissue growth factor (CTGF/CCN2) in a mouse model of rhabdomyosarcomagenesis. 160
Inhibition of prostate carcinogenesis by combined active immunoprophylaxis. 158
Immune-infiltrate characterization in localized osteosarcoma patients treated within protocol ISG-OS1. 158
Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma 157
Immune prevention of mammary carcinogenesis in HER-2/neu transgenic mice: a microarray scenario. 157
The molecular basis of herpesviruses as oncolytic agents. 157
Totale 21.180
Categoria #
all - tutte 83.519
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 83.519


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.183 0 0 0 0 0 0 0 0 0 188 165 830
2021/20223.446 357 118 249 170 301 209 94 247 179 224 719 579
2022/20233.856 439 451 204 502 262 268 123 202 529 152 347 377
2023/20241.494 71 166 98 152 132 181 85 271 50 98 82 108
2024/20254.336 292 542 330 277 640 260 309 189 68 309 243 877
2025/20269.636 1.110 1.102 935 813 1.075 540 923 332 2.023 783 0 0
Totale 32.194